Summary:
- The U.S. Food and Drug Administration (FDA) has approved the use of Nucala (mepolizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP).
- Nucala is a monoclonal antibody that helps reduce inflammation in the nasal passages, which can help alleviate the symptoms of CRSwNP, such as nasal congestion, nasal polyps, and difficulty breathing.
- This approval provides a new treatment option for adults with CRSwNP, a chronic condition that can significantly impact a person's quality of life and is often difficult to manage.